$MOLN News

Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Molecular Partners Highlights Multispecific Radio-DARPins Formatted As Bispecific Or 2-In-1 DuoDARPin To Address Tumor Heterogeneity

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Molecular Partners Updates Pipeline As MP0712 Dosing Continues, NuMeRI Initiates Compassionate Care With 225Ac DLL3 Radio-DARPin, And MP0726 Imaging Targeted For Second Half Of 2026

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

Molecular Partners And Orano Med Dose First Patients In DLL3-Targeting Radio-DARPin Small Cell Lung Cancer Study

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

Molecular Partners Q1 EPS $(0.45) Misses $(0.38) Estimate

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Molecular Partners Announces Publication Of Phase 1 Clinical Data In 'Nature Cancer' That Illustrate The Potential Of Tumor-Localized CD40 Agonist, MP0317, To Modulate The Tumor Microenvironment

HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target

Reported Sunday, Molecular Partners Nominates MP0632 As First Logic-Gated Switch-DARPin T Cell Engager Candidate For MSLN/EpCAM-Expressing Solid Tumors With Favorable Therapeutic Window At AACR 2026

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712